Tag: AD109

All

Phase 3 Data Published for Once-Nightly OSA Drug Candidate AD109

Results from the SynAIRgy trial show the investigational oral therapy AD109 significantly reduced airway obstruction and improved oxygenation in patients with obstructive sleep apnea.

All

First Patient Dosed in Second Phase 3 Trial of Oral Treatment for OSA

SynAIRgy compares AD109 to placebo over six months in people with OSA who are intolerant of or refuse positive airway pressure therapy.

All

Apnimed’s Sleep Apnea Drug Candidate Improves Daytime Impairment, In Addition to Lowering AHI

Apnimed announced positive topline results from the MARIPOSA Phase 2b trial, a study of its lead drug candidate for obstructive sleep apnea.

Apnimed to Present Data on Investigational Oral Treatment for Sleep Apnea

May 16, 2023 | Emerging Compounds, Obstructive Sleep Apnea

Data from the phase 2b trial of Apnimed’s leading drug candidate for OSA will be featured at The American Thoracic Society’s ATS 2023 International Conference in Washington, DC.

Tag: AD109

All

Phase 3 Data Published for Once-Nightly OSA Drug Candidate AD109

OSA Oral Drug Trial Success Positions Apnimed to File New Drug Application in 2026

GLP-1 Medications Show Promise as First Drug Therapy for Sleep Apnea

Apnimed Completes Enrollment Early in Phase 3 Study for Oral OSA Treatment

Most Sleep Apnea Patients Aren’t Obese, Apnimed Study Finds

Apnimed Completes Enrollment for Phase 3 Sleep Apnea Drug Trial

Apnimed Strengthens Leadership Amid OSA Drug Development

All

First Patient Dosed in Second Phase 3 Trial of Oral Treatment for OSA

Joint Venture Seeks to Develop Oral Therapies for Sleep Apnea

Apnimed to Showcase Latest Findings on Investigational OSA Drug

Sleep Apnea Drug Candidate Significantly Improves Symptoms in Phase 2b Trial

First Patient Dosed in Phase 3 Trial of OSA Drug Candidate AD109

Apnimed to Share New Data on AD109 and AD113 for OSA

Apnimed’s AD109 Pill Lowers AHI for a Month. Can Its Sleep Apnea Safety and Efficacy Data Extend a Year?

Apnimed Presents Positive Results of Sleep Apnea Drug Candidate

All

Apnimed’s Sleep Apnea Drug Candidate Improves Daytime Impairment, In Addition to Lowering AHI

FDA Grants Fast Track Designation to Apnimed Sleep Apnea Drug Candidate AD109

Apnimed Raises $62.5M to Advance Lead Sleep Apnea Pill Candidate to Phase 3

New Studies: Sleep Apnea Pill Shows Durability of Effect & Improved Quality of Life in Mild to Severe OSA

Apnimed to Present Data on Investigational Oral Treatment for Sleep Apnea

Sleep Review

Our Parent Company

Key Resources

Helpful Links